Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab vs Adalimumab Dose Intensification in Crohn's Disease (VEDIAN)
NCT06180382Phase 4Recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of vedolizumab, adalimumab in Crohn's disease, sponsored by CHU Saint-Etienne. Started Oct 2024; status: recruiting.
02
Drugs
vedolizumabadalimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06180382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180382.